AU2020203976A1 — Combination therapy
Assigned to Aerie Pharmaceuticals Inc · Expires 2020-07-02 · 6y expired
What this patent protects
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compo…
USPTO Abstract
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt. 1/3 0.5% ROCKI Combinations -0-Travatan Z (n=5) 0 ... -- ---------------- ---- -------- -o- Lumigan (n=6) 2 .............................................. -t-Xalatan (n=3) -23 ----- -- --- ...--------------------------.. .. .. ... .. ... .. ... .. .. ... .. ... .. ... .. . E EL - ..................I- -------------------------------- - ---- - --.-. 0 -5 -------------------- --- ---. - .........-...-. ---- ------ ------- --- -------- -7 - ... .... ------ ------- - -- - ------ ---------- - ------- .... ...... -7 . .- -- -- .. .., .... .. ..... ........ ... . -8 0 8 16 24 32 40 48 56 64 72 80 time (hours) FIGURE 1
Drugs covered by this patent
- Xalatan (LATANOPROST) · Thea Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.